Reach Us +441467840001
Drug Chimerism As A Fusion Of Two Anticancer Chemotherapeutics Into One Entity: Discovery Of Potent Molecular Chimera CM358 For Treatment Of Metastatic Melanoma | 52511
ISSN: 2161-0444

Medicinal Chemistry
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Drug chimerism as a fusion of two anticancer chemotherapeutics into one entity: Discovery of potent molecular chimera CM358 for treatment of metastatic melanoma

International Conference on Pharmaceutical Chemistry

Gary Gellerman

Ariel University, Israel

ScientificTracks Abstracts: Med chem

DOI: 10.4172/2161-0444.C1.024

Resistance to drugs that cancer cells develop and the inherent capability of these cells to survive the drug treatment, produces a great motivation to look for new techniques of chemotherapeutic cure and search for novel anti-proliferative agents. In the present report, we demonstrate a facile synthetic strategy towards the discovery of new anti-cancer substances. This strategy is based on simple covalent coupling between known anti-cancer drugs, which results in novel ‘chimeric’ small molecules. One of the novel compounds presented here, CM358, is a result of amide bond formation between known Topo II inhibitor amonafide (AM) and DNA mustard alkylator chlorambucil (CLB). It demonstrates a significant cytotoxic predominance over the equimolar mixture of AM and CLB in various cancer cell lines and in xenograft model of human metastatic melanoma. Modeling studies and FACS analysis of CM358 will also be presented.

Gary Gellerman has completed his PhD from Tel Aviv University in 1994 and joined Compugen Ltd. In 2000, he accepted the position of Vice-president, Molecular Diversity in Compugen where he was responsible for developing drug discovery platform. In 2005, he moved to Ariel University, currently holding Deanship of Faculty of Natural Sciences. He has published more than 50 articles in reputed journals.

Email: [email protected]